EU Sunscreen Actives and the FDA's OTC Drug Gate: What European Brands Must Know Before Exporting to the US

Tinosorb S has been a staple in European sun care formulations for more than twenty years. It’s photostable, broad-spectrum, and performs exceptionally well in lightweight textures — the kind of UV filter that makes a formulator’s life considerably easier. But the moment a European brand tries to sell a Tinosorb S-containing sunscreen in the United States, they hit an immediate and significant wall: Tinosorb S is not on the FDA’s approved list of sunscreen active ingredients. Not under review, not provisionally accepted. Simply absent.

This isn’t a technicality. It’s a fundamental regulatory mismatch that catches European sunscreen brands off-guard more reliably than almost any other cross-Atlantic compliance issue. And it stems from a single, counterintuitive fact: sunscreens are cosmetics in the EU and drugs in the US.

Cosmetics in Brussels, OTC Drugs in Washington

Under EU Regulation 1223/2009, sunscreens are treated as cosmetic products. Brands select UV filters from Annex VI — the permitted list of UV-screening substances — complete the Safety Assessment required under Annex I, and notify the finished product through the CPNP portal before placing it on the European market. The product is a cosmetic. The Responsible Person carries the regulatory burden. Done.

Cross the Atlantic, and the regulatory category changes entirely. In the United States, sunscreens are classified as over-the-counter (OTC) drugs by the FDA, governed by the Federal Food, Drug, and Cosmetic Act. The active sunscreen ingredients are drug ingredients. The product must carry a Drug Facts label formatted to 21 CFR Part 201 specifications. And the manufacturing facility must comply with pharmaceutical-grade current Good Manufacturing Practice — not ISO 22716 cosmetics GMP, but 21 CFR Part 211 pharmaceutical manufacturing standards. These two frameworks are not interchangeable, and assuming they are is an expensive mistake.

This classification isn’t obscure regulatory trivia. It fundamentally changes what a European sunscreen brand must do, build, and budget before a single unit reaches a US shelf.

The EU Permitted Filter List vs. What the FDA Actually Recognises

This is where the practical pain becomes concrete. EU Annex VI permits more than 25 UV filter substances for use in cosmetic sunscreens. That list includes some of the most technically sophisticated modern filters in commercial use: Tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl triazine), Tinosorb M (methylene bis-benzotriazolyl tetramethylbutylphenol), Mexoryl SX (ecamsule), Mexoryl XL (drometrizole trisiloxane), and Uvasorb HEB (diethylhexyl butamido triazone), among others. These have been evaluated by the EU’s Scientific Committee on Consumer Safety (SCCS) and cleared for use at defined maximum concentrations.

The FDA’s OTC Sunscreen Monograph, updated through the CARES Act OTC Monograph Reform framework, recognises 16 active sunscreen ingredients in total. But of those 16, the FDA’s 2021 Final Administrative Order — which took full effect in September 2021 — confirmed only 2 as generally recognised as safe and effective (GRASE): zinc oxide and titanium dioxide. Two ingredients, PABA and trolamine salicylate, were classified as not GRASE. The remaining 12 — including widely used ingredients like avobenzone, oxybenzone, and octinoxate — were placed in a provisional “insufficient data” category requiring additional safety information before their status can be finalised.

What that means for a European brand is stark. The EU filters that European formulators rely on most — the ones delivering superior UVA coverage and elegant photostability — have no pathway to US shelves under the current OTC monograph at all. Tinosorb and the Mexoryl filters aren’t among the 16. They sit entirely outside the FDA’s approved universe.

How New Sunscreen Actives Can Reach the FDA — In Theory

Congress attempted to address this gap by passing the Sunscreen Innovation Act (SIA) in 2014. The SIA established a new review process, called Time and Extent Applications (TEAs), through which manufacturers or trade associations can petition the FDA to evaluate new sunscreen active ingredients. Once an application is formally accepted, the FDA has 300 days to issue a proposed order on that ingredient’s GRASE status.

On paper, this created a realistic route for EU sunscreen actives to enter the US market. In practice, that route has been largely impassable. As of mid-2026, no new active ingredient submitted under the SIA pathway has received a final GRASE determination from the FDA. Applications for ingredients including ecamsule (Mexoryl SX), championed by L’Oréal since the early 2000s, have remained in indefinite review. The FDA has consistently cited the need for additional data — particularly around photocarcinogenicity, endocrine effects, and systemic absorption — that applicants have found both costly and time-consuming to generate.

The honest assessment: if your European sunscreen brand is planning US market entry within a three-to-five year horizon and counting on FDA approval of a non-monograph active ingredient, that plan is almost certainly not viable.

The Two Realistic Paths to the US Sunscreen Market

For European brands serious about the US, the options narrow to two.

Reformulate specifically for the US market. This means building a US-specific formula using only FDA-recognised active ingredients — in practice, the most defensible approach today is to lead with zinc oxide and titanium dioxide (both confirmed GRASE), potentially combined with avobenzone or other Category III ingredients, which may still be marketed while the FDA’s safety review is ongoing under existing conditions. The trade-offs are real. European sun care products often achieve their lightweight, elegant texture precisely because they rely on chemical filters. A formula repositioned around zinc oxide or titanium dioxide at effective SPF concentrations behaves differently in texture and may require significant aesthetic reformulation work alongside the regulatory shift. But reformulation is the only commercially viable path for most brands, and the premium “mineral sunscreen” positioning actually resonates well with US consumers in the clean beauty segment.

Qualify as an OTC drug manufacturer. A US sunscreen isn’t only a formulation challenge — it’s a quality system overhaul. The manufacturing site (whether your own facility or a contract manufacturer) must be registered with the FDA as a drug establishment, must demonstrate compliance with 21 CFR Part 211 pharmaceutical cGMP, and must show that every released batch meets drug-grade manufacturing standards. The gap between ISO 22716 and 21 CFR Part 211 is real and significant. Drug GMP introduces stricter controls on equipment qualification, cleaning validation methodology, analytical testing of in-process materials, and the documentation standards expected at batch release. European brands operating under ISO 22716 have a strong foundation in quality thinking — but a formal gap assessment against 21 CFR Part 211 is not optional. It’s the starting point, not a formality.

Labelling: Where European Brands Most Consistently Stumble

SPF labelling is a further source of divergence that catches European brands unprepared. The FDA limits SPF claims to “SPF 50+” for any product testing above SPF 50 — a rule in place since 2012. Products cannot label themselves SPF 60, SPF 70, or any specific value above 50. This differs from common European commercial practice, where higher SPF values are often communicated explicitly.

Beyond SPF numbers, the entire label architecture must be rebuilt. The Drug Facts panel format is specified under 21 CFR Part 201 and the OTC labelling requirements leave very little room for creative interpretation. Required warnings, active ingredient declarations, inactive ingredient listings, and the broad-spectrum claim language (only permitted when the product passes FDA’s critical wavelength test at ≥370 nm) all follow a prescribed format. The INCI-format cosmetic ingredient list, the Responsible Person declaration, and other elements familiar from EU cosmetics compliance do not appear on a US OTC sunscreen label at all.

Getting this wrong carries serious consequences. An FDA inspector identifying a non-compliant Drug Facts panel on a sunscreen product can treat it as a misbranding violation — at which point the product is legally adulterated and cannot be imported or sold in the US. Import alerts based on misbranding have delayed and disrupted US launches for European brands that underestimated this dimension of compliance.

What to Resolve Before You Commit to a US Launch

If your brand has built its European reputation on a high-SPF, chemically-filtered sun care range, the regulatory realities above need to shape your investment decisions before any commercial commitments are made in the US.

Start with a formulation audit against the FDA-recognised active ingredient list. If your formula includes Tinosorb, Mexoryl, Uvasorb, or any EU-approved active not present in the FDA monograph, a US-specific reformulation is required — full stop. That reformulated product then needs SPF efficacy testing under the FDA’s own test protocol (which differs from ISO 24444 used in the EU) and broad-spectrum verification using the FDA critical wavelength method.

In parallel, assess your manufacturing site’s current GMP posture against 21 CFR Part 211. If the site holds ISO 22716 only, commission a formal gap assessment before assuming compliance. For brands using European CMOs, this often involves a conversation that CMO partners are not always eager to have — which is exactly why it needs to happen early in the process, not after retail contracts are signed.

The US sun care market generates well over $2 billion in annual consumer spend, and European heritage brands genuinely do carry premium positioning potential in that environment. But the compliance investment is front-loaded and non-negotiable. The brands that successfully make the transition don’t try to translate their EU regulatory file to the US. They build a US programme from scratch, informed by their European expertise but grounded entirely in FDA requirements.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• FDA SPF Testing and OTC Sunscreen Drug Compliance — Qalitex Laboratories provides ISO 17025-accredited SPF testing and OTC drug compliance support for brands entering the US market.
• Health Canada Sunscreen and OTC Drug Registration for European Brands — Androxa supports European brands navigating Canada’s distinct sunscreen classification and NPN licensing requirements.